Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
SAB Biotherapeutics (SABS)
NASDAQ:SABS
RESEARCH TOOLSreports
SAB Biotherapeutics (SABS) Stock Price & Analysis
62 Followers
SABS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.36 - $10.50
Previous Close$2.86
Volume896.00
Average Volume (3M)16.04K
Market Cap
$26.40M
Enterprise Value-$24.26M
Total Cash (Recent Filing)$56.57M
Total Debt (Recent Filing)$5.91M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 07, 2024EPS Estimate
-$1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.74
Shares Outstanding9,229,274
10 Day Avg. Volume15,703
30 Day Avg. Volume16,042
Standard Deviation0.31
R-Squared0.02
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)1.72
Price to Sales (P/S)11.71
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-12.55
Enterprise Value/Gross Profit-10.84
Enterprise Value/Ebitda1.05
Forecast
1Y Price Target
$7.00Price Target Upside138.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
SAB Biotherapeutics News
PremiumPress Releases
SAb Biotherapeutics Rebrands as SAB BIO
PremiumCompany Announcements
SAB Biotherapeutics Appoints Mr. Conley, Details Public Disclosure
Bulls Say, Bears Say
Bulls Say
EarningsSAB reported 1Q24 EPS of ($0.54), versus the estimate of ($0.98), and the full-year 2024 EPS estimate has been increased.
Financial PositionThe company secured a private placement providing up to $110M in gross proceeds, ensuring sufficient cash to fund operations into 2026.
Regulatory ProgressFDA clearance of IND for SAB-142 in type 1 diabetes signals regulatory progress for the company.
Bears Say
Financial PerformanceSAB reported 4Q23 EPS of ($3.38), versus the estimate of ($0.64) due to several one-time charges, leading to a decrease in the full-year 2024 EPS estimate to ($4.90) from ($1.78).
Financial PerformanceSAB reported 4Q23 EPS of ($3.38), versus the estimate of ($0.64) due to several one-time charges, leading to a decreased full-year 2024 EPS estimate.
RisksRisks associated with the company's progress include commercial, regulatory, clinical, manufacturing, financial, liability, and intellectual challenges.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SABS FAQ
What was SAB Biotherapeutics’s price range in the past 12 months?
SAB Biotherapeutics lowest stock price was $2.36 and its highest was $10.50 in the past 12 months.
What is SAB Biotherapeutics’s market cap?
Currently, no data Available
When is SAB Biotherapeutics’s upcoming earnings report date?
SAB Biotherapeutics’s upcoming earnings report date is Aug 07, 2024 which is in 34 days.
How were SAB Biotherapeutics’s earnings last quarter?
SAB Biotherapeutics released its earnings results on May 20, 2024. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.96 by $0.42.
Is SAB Biotherapeutics overvalued?
According to Wall Street analysts SAB Biotherapeutics’s price is currently Undervalued.
Does SAB Biotherapeutics pay dividends?
SAB Biotherapeutics does not currently pay dividends.
What is SAB Biotherapeutics’s EPS estimate?
SAB Biotherapeutics’s EPS estimate is -$1.15.
How many shares outstanding does SAB Biotherapeutics have?
SAB Biotherapeutics has 9,229,274 shares outstanding.
What happened to SAB Biotherapeutics’s price movement after its last earnings report?
SAB Biotherapeutics reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.96. Following the earnings report the stock price went down -15.652%.
Which hedge fund is a major shareholder of SAB Biotherapeutics?
Among the largest hedge funds holding SAB Biotherapeutics’s share is RA Capital Management. It holds SAB Biotherapeutics’s shares valued at N/A.
---
SAB Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (138.91% Upside)
$7.00 (138.91% Upside)
Hedge Fund Trend
Decreased
By 237.2K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.54%
12-Months-Change
Fundamentals
Return on Equity
-103.25%
Trailing 12-Months
Asset Growth
67.25%
Trailing 12-Months
Company Description
SAB Biotherapeutics
Blue Calypso Inc is engaged in the development, sales, delivery and licensing of technology and intellectual property focused on mobile shopper engagement, digital word of mouth and location-based marketing and advertising. Its solutions include mobile engagement, POP and merchandise tracking, mobile plant tag engagement. The company derives its revenues from the cloud-based consumption of its technology platform, consulting fees and licensing of its technologies.
---
SABS Stock 12 Month Forecast
Average Price Target
$7.00
▲(138.91% Upside)
Technical Analysis
Aptose Biosciences
―
Sorrento Therapeutics
―
Adaptimmune Therapeutics
―
Clearside Biomedical
―
Best Analysts Covering SABS
1 Year
1 Year Success Rate
0/11 ratings generated profit
1 Year Average Return
-39.45%
reiterated a buy rating last month
Copying Edward White's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -39.45% per trade.
---